- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03463057
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL (HO151DLBCL)
A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Antwerpen, Belgium
- BE-Antwerpen-ZNASTUIVENBERG
-
Antwerpen, Belgium
- BE-Antwerpen Edegem-UZA
-
Brugge, Belgium
- BE-Brugge-AZBRUGGE
-
Leuven, Belgium
- BE-Leuven-UZLEUVEN
-
Roeselare, Belgium
- BE-Roeselare-AZDELTA
-
-
-
-
-
Amersfoort, Netherlands
- NL-Amersfoort-MEANDERMC
-
Amsterdam, Netherlands
- NL-Amsterdam-OLVG
-
Amsterdam, Netherlands
- NL-Amsterdam-VUMC
-
Apeldoorn, Netherlands
- NL-Apeldoorn-GELREAPELDOORN
-
Breda, Netherlands
- NL-Breda-AMPHIA
-
Delft, Netherlands
- NL-Delft-RDGG
-
Den Bosch, Netherlands
- NL-Den Bosch-JBZ
-
Den Haag, Netherlands
- NL-Den Haag-HAGA
-
Dordrecht, Netherlands
- NL-Dordrecht-ASZ
-
Ede, Netherlands
- NL-Ede-ZGV
-
Eindhoven, Netherlands
- NL-Eindhoven-CATHARINA
-
Eindhoven, Netherlands
- NL-Eindhoven-MAXIMAMC
-
Enschede, Netherlands
- NL-Enschede-MST
-
Groningen, Netherlands
- NL-Groningen-UMCG
-
Hilversum, Netherlands
- NL-Hilversum-TERGOOI
-
Hoofddorp, Netherlands
- NL-Hoofddorp-SPAARNEGASTHUIS
-
Leeuwarden, Netherlands
- NL-Leeuwarden-MCL
-
Leiden, Netherlands
- NL-Leiden-LUMC
-
Maastricht, Netherlands
- NL-Maastricht-MUMC
-
Nieuwegein, Netherlands
- NL-Nieuwegein-ANTONIUS
-
Nijmegen, Netherlands
- NL-Nijmegen-CWZ
-
Rotterdam, Netherlands
- NL-Rotterdam-ERASMUSMC
-
Rotterdam, Netherlands
- NL-Rotterdam-MAASSTADZIEKENHUIS
-
Sittard, Netherlands
- NL-Sittard-Geleen-ZUYDERLAND
-
Tilburg, Netherlands
- NL-Tilburg-ETZ
-
Utrecht, Netherlands
- NL-Utrecht-UMCUTRECHT
-
Zwolle, Netherlands
- NL-Zwolle-ISALA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-75 (inclusive) years
- Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma (DLBCL-NOS) based upon a representative histology specimen according to the World Health Association (WHO) classification, revision 2016
- Ann Arbor stages II-IV
- WHO performance status 0 - 1
- International Prognostic Index (IPI) ≥ 3 at diagnosis
- Complete metabolic remission (Deauville 1-3) after 6-8 cycles of R-CHOP according to the Lugano criteria
Of note:
- Rituximab may have been administered either intravenously or subcutaneously. A rituximab biosimilar may have been used when it is approved for the indication of DLBCL.
- Patients should have received at least 6 cycles R-CHOP. Dose reductions for vincristine are allowed during R-CHOP. Dose reductions because of bone marrow toxicity are allowed but cannot exceed >15% of cumulative dose of doxorubicin and cyclophosphamide.
- Central nervous system prophylaxis (MTX) by intrathecal therapy or IV is allowed.
- Fludeoxyglucose Positron Emission Tomography (18F-FDG-PET) scan should have been made 4-8 weeks after last induction cycle
Histologically confirmed false positive EoT PET-scans are eligible.
- Negative pregnancy test at study entry
- Patient is willing and able use adequate contraception during and until 5 months after the last protocol treatment.
- Patient is capable of giving a written informed consent
Exclusion Criteria:
Diagnosis
• All histopathological diagnoses other than DLBCL-NOS according to the WHO classification, revision 2016, including:
- High-grade B-cell lymphoma with a double/triple translocation with MYC, BCL2 and/or BCL6. Please note that patients with an isolated MYC translocation or an isolated BCL2 translocation or an isolated BCL-6 translocation are eligible (single hit translocation).
- Testicular large B-cell lymphoma
- Primary mediastinal B cell lymphoma
- Transformed indolent lymphoma
- Post-transplant lymphoproliferative disorder
Organ dysfunction
- Clinical signs of severe pulmonary dysfunction
- Clinical signs of heart failure (New York Heart Association (NYHA) classification II-IV)
- Symptomatic coronary artery disease or cardiac arrhythmias not well controlled with medication.
- Myocardial infarction during the last 6 months
- Significant renal dysfunction (serum creatinine ≥ 150 umol/l or clearance ≤ 30ml/min
Creatinine clearance (CrCl) may be calculated by Cockcroft -Gault formula:
CrCl = (140 - age [in years]) x weight [kg] (x 0.85 for females)/(0.815 x serum creatinine [μmol/L])
• Inadequate hematological function: hemoglobin < 5.5 mmol/L Absolute Neutrophil Count (ANC) < 1.0x10↑9/L or platelets < 75x10↑9 /L
- Signs or known history of bleeding disorder.
- Significant hepatic dysfunction (total bilirubin ≥ 1.5x upper limit of normal (ULN) or transaminases ≥ 2.5 x ULN), unless related to Gilberts syndrome.
- Clinical signs of severe cerebral dysfunction
- Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
- Major surgery within the last 4 weeks
Known or suspected infection • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks of the start of Cycle 1. Suspected active or latent tuberculosis needs to be confirmed by positive interferon gamma (IFN-γ) release assay
• Patients known to be Human Immuno-deficiency Virus (HIV)-positive
- Active chronic hepatitis B or C infection
- Administration of a live, attenuated vaccine within 4 weeks before date of registration or anticipation that such a live attenuated vaccine will be required during the study and for a period of 5 months after discontinuation of atezolizumab
Auto-immune • Any active or history of documented autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
The following exceptions are allowed: Patients with autoimmune-related hypothyroidism or type 1 diabetes mellitus who are on stable treatment.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest computer tomography (CT) scan at screening.
- Patients with uncontrolled asthma or allergy, requiring systemic steroid treatment
- Regular treatment with corticosteroids within the 4 weeks prior to date of registration, unless administered for indications other than NHL at a dose equivalent to < 30 mg/day prednisone/prednisolone
General
• Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease)
• Current participation in another clinical trial interfering with this trial
• History of active cancer during the past 5 years, except basal cell carcinoma of the skin, stage 0 cervical carcinoma or carcinoma in situ (for which no systemic treatment was indicated)
• Life expectancy < 6 months
• Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Prior treatment
- Prior treatment with Atezolizumab, or anti-programmed cell death protein-1 (anti PD-1) or PDL-1 antibodies.
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA4 therapeutic antibodies.
- Treatment with systemic immunostimulatory agents (including but not limited to IFN, interleukin [IL]-2) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1.
- Treatment with systemic immunosuppressive medications, including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) agents within 2 weeks prior to date of registration; inhaled corticosteroids and mineralocorticoids are allowed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Atezolizumab
18 cycles atezolizumab followed by 12 months of observation
|
Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease free survival (DFS) measured from the date of registration to relapse or death from any cause whichever comes first.
Time Frame: 2 year after inclusion last patient
|
To evaluate the 2-year DFS for patients in complete metabolic remission after R-CHOP induction
|
2 year after inclusion last patient
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
(Severe) Adverse Events and the relation of adverse events in time to the recovery of the T-cell repertoire.
Time Frame: 2 years after inclusion last patient
|
To evaluate toxicity and assess the relation of adverse events in time to recovery of the T-cell repertoire.
|
2 years after inclusion last patient
|
Overall survival (OS), calculated from registration until death from any cause. Patients still alive or lost to follow up are censored at the last date known to be alive.
Time Frame: 2 years after inclusion last patient
|
To evaluate the 2-year OS.
|
2 years after inclusion last patient
|
The relationship between MRD status at the end-of-induction and end-of-consolidation therapy.
Time Frame: 2 years after inclusion last patient
|
To evaluate MRD status at the end of induction therapy, at various time points during consolidation treatment and at the end of consolidation.
|
2 years after inclusion last patient
|
The relation between MRD conversion and 2-years DFS and OS.
Time Frame: 2 years after inclusion last patient
|
To evaluate if there is a relation between MRD conversion and 2-years DFS and OS.
|
2 years after inclusion last patient
|
The relation between the T-cell and NK cell repertoire and adverse events.
Time Frame: 2 years after inclusion last patient
|
To evaluate the recovery of the T-cell and NK cell repertoire after induction therapy and at various time points during consolidation treatment in relation to toxicity and efficacy.
|
2 years after inclusion last patient
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Atezolizumab spinal fluid concentration as assessed by spinal fluid measurements will be performed in patients receiving atezolizumab.
Time Frame: 2 years after inclusion last patient
|
To assess the crossing of the blood-brain barrier of atezolizumab by measuring atezolizumab concentrations in het cerebrospinal fluid.
|
2 years after inclusion last patient
|
Collaborators and Investigators
Investigators
- Principal Investigator: M. Nijland, PhD/MD, NL-Groningen-UMCG
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HO151
- 2017-002605-35 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NHL
-
National Cancer Institute (NCI)Completed
-
Beijing Immunochina Medical Science & Technology...Unknown
-
Shengke Pharmaceuticals Pty LtdTerminatedLeukemia | NHLAustralia
-
Duke UniversityTerminated
-
EdiGene (GuangZhou) Inc.The First Affiliated Hospital of Henan University of Science and TechnologyActive, not recruitingRelapsed or Refractory B-cell Malignancy(NHL/ALL)China
-
Alexion PharmaceuticalsPortola PharmaceuticalsCompletedFollicular Lymphoma (FL/Indolent NHL) | Aggressive NHL (a NHL) | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | T-cell Lymphoma (PTCL and CTCL) | B-cell Non Hodgkin Lymphoma (NHL)United States
-
BioNova Pharmaceuticals (Shanghai) LTD.Withdrawn
-
Gilead SciencesCompleted
-
Calithera Biosciences, IncCompletedMultiple Myeloma | Non-Hodgkin's Lymphoma (NHL) | Waldenstrom's Macroglobulinemia (WM) | Other B-cell NHL Subtypes, Including WM | T-cell NHLUnited States
-
Mundipharma Research LimitedTerminatedIndolent B-cell NHLAustralia, Slovakia
Clinical Trials on Atezolizumab
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Intergroupe Francophone de Cancerologie ThoraciqueRoche Pharma AG; GFPCCompletedSmall Cell Lung CancerFrance
-
Yonsei UniversityNot yet recruitingNon-small Cell Lung CancerKorea, Republic of
-
First Affiliated Hospital of Zhejiang UniversityHoffmann-La Roche; Geneplus-Beijing Co. Ltd.UnknownNon-Small Cell Lung CancerChina
-
Corvus Pharmaceuticals, Inc.Genentech, Inc.CompletedRenal Cell Cancer | Metastatic Castration Resistant Prostate CancerUnited States, Canada, Australia
-
Incyte CorporationHoffmann-La Roche; Genentech, Inc.TerminatedUC (Urothelial Cancer) | NSCLC (Non-small Cell Lung Carcinoma)United States
-
Seoul National University HospitalUnknown
-
Chonnam National University HospitalRoche Pharma AGCompletedLung Neoplasm MalignantKorea, Republic of
-
Astellas Pharma Global Development, Inc.CompletedAcute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) MutationUnited States
-
The Netherlands Cancer InstituteRoche Pharma AGCompletedBreast Cancer | Ovarian Cancer | Cervix Cancer | Endometrial CancerNetherlands